Talazoparib 1 mg (Talzenna) is a medication used for the treatment of hereditary breast cancer (specifically BRCA-mutated breast cancer) and other cancers with certain DNA repair deficiencies. It is marketed under the brand name Talzenna and belongs to the class of drugs known as PARP inhibitors.

Talazoparib 1 mg (Talzenna)

Product Overview: Talazoparib 1 mg (Talzenna) is a PARP inhibitor used to treat HER2-negative, BRCA-mutated breast cancer in patients with metastatic or locally advanced breast cancer. Talazoparib works by inhibiting poly (ADP-ribose) polymerase (PARP), an enzyme involved in DNA repair. By blocking this enzyme, Talazoparib prevents cancer cells from repairing damaged DNA, leading to cell death and tumor shrinkage.

Key Benefits:

• Targeted therapy for BRCA-mutated breast cancer, improving survival and progression-free survival rates.
• Oral medication, offering convenience for patients as an alternative to intravenous treatments.
• Helps prevent the repair of cancer cell DNA, leading to cancer cell death.

Indications:

• Metastatic or locally advanced breast cancer in patients with a BRCA mutation (either inherited or somatic).
• Approved for use in HER2-negative breast cancer.
• Typically used when other therapies have not been effective or appropriate for the patient.

Dosage:

• The usual recommended dose is 1 mg taken orally once daily.
• Talazoparib should be taken with or without food.
• Treatment duration depends on the individual patient’s response and side effects, and should be determined by a healthcare provider.

Precautions:

• Blood cell count should be monitored regularly, as Talazoparib may cause anemia, neutropenia, or thrombocytopenia.
• Patients should be evaluated for any bone marrow suppression before starting therapy.
• Not recommended for pregnant or breastfeeding women, as it may harm the baby.
• Consult your healthcare provider if you have liver or kidney problems, or if you are planning a pregnancy.

Common Side Effects:

• Fatigue
• Nausea
• Anemia
• Headache
• Decreased appetite
• Low white blood cell count (neutropenia)
• Low platelet count (thrombocytopenia)

Packaging:

• Talazoparib 1 mg (Talzenna) tablets are packaged in [insert packaging type] for safe, convenient oral administration.

Important Notes:

• Talazoparib is a prescription medication and should only be used under the guidance of a qualified healthcare provider.
• Regular monitoring is essential during treatment, particularly blood counts and signs of bone marrow suppression.
• Store in a cool, dry place, away from direct sunlight.